Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ADCT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.2
1 Year Target Price $8.2
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 351.62% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 341.27M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 6 | Beta 1.96 | 52 Weeks Range 1.05 - 3.98 | Updated Date 07/16/2025 |
52 Weeks Range 1.05 - 3.98 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -197.64% | Operating Margin (TTM) -123.58% |
Management Effectiveness
Return on Assets (TTM) -27.03% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 304470726 | Price to Sales(TTM) 4.5 |
Enterprise Value 304470726 | Price to Sales(TTM) 4.5 | ||
Enterprise Value to Revenue 4.02 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 112261000 | Shares Floating 79158157 |
Shares Outstanding 112261000 | Shares Floating 79158157 | ||
Percent Insiders 21.59 | Percent Institutions 67.58 |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA is a commercial-stage biotechnology company dedicated to improving the lives of patients with cancer by creating highly targeted antibody drug conjugates (ADCs). Founded in 2011, it has focused on developing a proprietary PBD-based ADC technology.
Core Business Areas
- Research and Development: Focuses on discovering and developing novel ADCs for hematological malignancies and solid tumors.
- Commercialization: Marketing and selling approved ADC therapies, such as ZYNLONTA.
Leadership and Structure
The company has a management team led by the CEO, supported by a board of directors. The structure includes departments for R&D, clinical development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- ZYNLONTA (loncastuximab tesirine-lpyl): ZYNLONTA is an ADC approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Market share data and revenue are not publicly available. Competitors include CAR-T therapies (Kymriah, Yescarta), other chemotherapies, and antibody therapies.
Market Dynamics
Industry Overview
The oncology market is a rapidly growing and competitive field, driven by advances in targeted therapies and immunotherapy. ADCs are a significant class of targeted therapies, offering the potential to deliver cytotoxic agents directly to cancer cells.
Positioning
ADC Therapeutics is positioned as a leader in the development of next-generation ADCs, leveraging its proprietary PBD technology. The company has a competitive advantage in its ability to create highly potent and targeted therapies.
Total Addressable Market (TAM)
The total addressable market for ADCs in oncology is estimated to be in the tens of billions of dollars. ADC Therapeutics is well-positioned to capture a significant share of this market with its pipeline of novel ADCs.
Upturn SWOT Analysis
Strengths
- Proprietary PBD-based ADC technology
- Approved product (ZYNLONTA) with demonstrated efficacy
- Experienced management team
- Strong pipeline of novel ADCs
Weaknesses
- Reliance on a single approved product
- High R&D expenses
- Competition from established pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expansion of ZYNLONTA to new indications
- Partnerships and collaborations with other pharmaceutical companies
- Advancement of pipeline assets to market
- Potential for breakthrough therapies in difficult-to-treat cancers
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Seagen (SGEN)
- ImmunoGen (IMGN)
- Daiichi Sankyo (DSNKY)
Competitive Landscape
ADC Therapeutics has a competitive advantage in its proprietary PBD technology but faces competition from larger, more established pharmaceutical companies. Seagen has a much larger share. The competition is fierce for ADC's.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by the advancement of its pipeline and the initial commercialization of ZYNLONTA.
Future Projections: Future growth is dependent on the success of its clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include expanding the clinical development program for ZYNLONTA, advancing pipeline assets, and forging partnerships.
Summary
ADC Therapeutics is a commercial-stage biotech company with a focus on antibody-drug conjugates. ZYNLONTA's sales and market adoption are key to its immediate success. The company needs to successfully navigate regulatory hurdles and competition. Advancing its pipeline assets and securing partnerships will be critical for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ADC Therapeutics SA Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.